following a full submission:
pembrolizumab (Keytruda®) is accepted for restricted use within NHSScotland.
Indication under review: as monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy.
SMC restriction: adults whose tumours express programmed death-ligand 1 (PD-L1) with less than 50% (0 to 49%) tumour proportion score (TPS).
In a randomised, phase III study pembrolizumab (as adjuvant therapy) was associated with statistically significant benefits in disease-free survival over placebo in patients with completely resected stage IB-IIIA non-small cell lung carcinoma.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
- SMC2689
- Indication:
As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum‑based chemotherapy.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 October 2024